Form 4: PAVM: Director Aklog Reports Stock Grant

PAVM Director Lishan Aklog reported the acquisition of 350,000 restricted shares under the company's Long-Term Incentive Equity Plan.

Summary

• Lishan Aklog, a Director and Chairman and CEO of PAVmed Inc. (PAVM), reported a transaction on April 2, 2026.
• This transaction involved the acquisition of 350,000 shares of common stock.
• These shares were granted as restricted stock under the Issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan.
• The restricted stock has a single vesting date of May 20, 2029, and is subject to forfeiture if the service period is not completed.
• Following this transaction, Aklog beneficially owns 357,614 shares of common stock directly and indirectly through various entities, including Pavilion Venture Partners LLC and HCFP/AG LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on a standard stock grant to a key executive, reflecting typical incentive practices rather than significant new financial information or strategic shifts.

Positives

• Grant of restricted stock to a key executive (Director, Chairman and CEO) indicates a commitment to long-term alignment of incentives.
• The grant of 350,000 shares suggests a significant investment in the company's future by management.
• The reporting person, Lishan Aklog, holds multiple key positions (Director, Chairman, CEO), indicating strong leadership involvement.

Negatives

• The restricted stock is subject to forfeiture, meaning the full benefit is contingent on continued service until May 20, 2029.
• The filing does not provide details on the performance conditions, if any, associated with the vesting of these restricted shares.

Risks

• The primary risk associated with the restricted stock is forfeiture if the requisite service period is not completed by May 20, 2029.
• Potential for dilution to existing shareholders if a large number of restricted stock grants vest and are exercised.

Future Outlook

The future outlook is tied to the vesting of the restricted stock on May 20, 2029, contingent upon the reporting person completing the requisite service period.

Industry Context

StockSavvy.ai notes that grants of restricted stock to senior management, as seen in this PAVmed Inc. filing, are a common practice across the healthcare technology sector to incentivize long-term performance and retention.

Stakeholder Impact

• Shareholders: The grant of restricted stock represents potential future dilution, but also signals management's commitment to long-term value creation.
• Employees: The incentive structure for senior leadership may influence overall company morale and retention strategies.
• Management: The grant reinforces the reporting person's role and incentivizes continued service and performance.

Next Steps

• Lishan Aklog must complete the requisite service period to avoid forfeiture of the restricted stock.
• The restricted stock is scheduled to vest on May 20, 2029.

Key Dates

Keywords

PAVM, PAVmed Inc., Form 4, Insider Trading, Stock Grant, Restricted Stock, Lishan Aklog, Director, CEO, Beneficial Ownership, Long-Term Incentive Plan